

Aligo Investment Fund – Derisking Innovation!

DERISKING

To allow inventions/technologies to exit university research labs and reach the market, there are many hurdles to overcome. One of the biggest hurdles is related to technological and business risks, while the technology or commercialization project is at a too early stages to attract strategic or financial partners. Since its creation in 2014, the Aligo Fund has been able to act at these early stages by, for example, validating inventions versus their commercial potential, establishing a proof of concept or a feasibility study, producing a functional prototype or generating data to improve claims in a patent.


Aligo Investment Fund has put \$3,3M in 44 projects or companies to support 35 technologies:

- 60% of these projects received an investment before a license was granted to a company
- Cumulative amounts invested range from \$5K to \$350K per technology

FINANCIAL LEVERAGE

Aligo's investment capacity has attracted both private and public co-financing and led to larger research, development or business projects.

- Overall, the leverage is 10x for a total amount of \$32.8 million.



IMPACTS

Aligo Fund has a different objective from the expected return requested by venture capital firms or angels investors. Indeed, the aim is to intervene sooner than these investors in order to give the best chance of success to a technology transfer, to generate economic wealth and to ensure that the results of public research have an impact in the society. For instance, Aligo's investments allow:

- Increase the value of a technology by reaching key value creation milestones
- Accelerate development
- Make a difference between whether or not a license is sign
- Drive the creation of companies

“From innovation to product is a long journey until you see the light at the end of the tunnel. It needs a group like Aligo to understand the opportunity when it is just a little light and a lot of tunnel, and to transform it in a viable vehicle for value creation, able to attract partnerships and capital. We were really fortunate to have such partner from the beginning.”

Radu Pislariu, PDG de Laurent Pharmaceuticals

The Aligo Fund's portfolio consists of intellectual property assets better-position for the market as well as innovative companies valued at more than \$200 million. Among these companies are Laurent Pharmaceuticals, MIMS, Noviflow, Ovensa, Sensequake, Spark Microsystems and Wrnch.